Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.

@article{Studeny2004MesenchymalSC,
  title={Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.},
  author={Matus Studeny and Frank C. Marini and Jennifer L Dembinski and Claudia Zompetta and Maria da Graça Cabreira-Hansen and Benjamin Nebiyou Bekele and Richard E. Champlin and Michael Andreeff},
  journal={Journal of the National Cancer Institute},
  year={2004},
  volume={96 21},
  pages={
          1593-603
        }
}
BACKGROUND High concentrations of interferon beta (IFN-beta) inhibit malignant cell growth in vitro. However, the therapeutic utility of IFN-beta in vivo is limited by its excessive toxicity when administered systemically at high doses. Mesenchymal stem cells (MSC) can be used to target delivery of agents to tumor cells. We tested whether MSC can deliver IFN-beta to tumors, reducing toxicity. METHODS Human MSC were transduced with an adenoviral expression vector carrying the human IFN-beta… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 374 CITATIONS, ESTIMATED 57% COVERAGE

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice

  • BioMed research international
  • 2014
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review

  • Stem Cell Research & Therapy
  • 2018
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Genetically modified mesenchymal stromal cells in cancer therapy

VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Mesenchymal stem cells for anti-cancer drug delivery.

  • Recent patents on anti-cancer drug discovery
  • 2013
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Myeloid-derived suppressor cells

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2005
2019

CITATION STATISTICS

  • 17 Highly Influenced Citations

  • Averaged 17 Citations per year from 2017 through 2019

  • 18% Increase in citations per year in 2019 over 2018

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily

JP JrEder, JG Supko, +3 authors DP Ryan
  • J Clin Oncol 2002:20:3772–84
  • 2002

Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002